Department of Psychology, Wake Forest University, Winston-Salem, NC 27109, USA.
Pharmacol Biochem Behav. 2010 Nov;97(1):144-51. doi: 10.1016/j.pbb.2010.05.024. Epub 2010 Jun 1.
Previous research has demonstrated that concurrent systemic administration of CB(1) cannabinoid and mu-opioid receptor agonists increases feeding in rats. However, the possible neural loci of this cooperative effect have yet to be identified. These studies tested whether the nucleus accumbens shell may be one site of the interactive effects of opioid and cannabinoid ligands on feeding. Injection of the mu-opioid agonist DAMGO (at 0, 0.025, 0.25, or 2.5 µg/0.5 µl/side) directly into the rat nucleus accumbens shell increased feeding on a sweetened-fat diet, and this effect was blocked by pretreatment with either the mu-opioid antagonist naltrexone (20 µg/0.5 µl/side) or the CB(1) antagonist SR141716 (0.5 µg/0.5 µl/side). Activation of nucleus accumbens shell CB(1) receptors with WIN55212-2 alone (at 0.1 or 0.5 µg/0.5 µl/side) had no apparent effect on food intake. However, local injections of the low dose of DAMGO (.025 µg/0.5 µl/side) in this region along with WIN55212-2 (at 0.25 or 0.50 µg/0.5 µl/side) increased feeding above that induced by DAMGO alone. These data suggest an important modulatory role for cannabinoid receptors in the expression of feeding behaviors in response to mu-opioid receptor activation of the nucleus accumbens shell.
先前的研究表明,同时给予 CB1 cannabinoid 和 mu 阿片受体激动剂会增加大鼠的摄食量。然而,这种协同作用的可能神经中枢尚未确定。这些研究测试了伏隔核壳是否是阿片类和大麻素配体对摄食的相互作用的一个可能的神经中枢。将 mu 阿片受体激动剂 DAMGO(0、0.025、0.25 或 2.5 µg/0.5 µl/侧)直接注射到大鼠伏隔核壳中会增加对加糖脂肪饮食的摄食量,而这种作用可被 mu 阿片受体拮抗剂纳曲酮(20 µg/0.5 µl/侧)或 CB1 拮抗剂 SR141716(0.5 µg/0.5 µl/侧)预处理阻断。单独激活伏隔核壳 CB1 受体(WIN55212-2,0.1 或 0.5 µg/0.5 µl/侧)对食物摄入没有明显影响。然而,在此区域注射低剂量 DAMGO(0.025 µg/0.5 µl/侧)与 WIN55212-2(0.25 或 0.50 µg/0.5 µl/侧)一起,会使摄食量增加,超过 DAMGO 单独作用引起的摄食量。这些数据表明大麻素受体在伏隔核壳 mu 阿片受体激活引起的摄食行为表达中具有重要的调节作用。